At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
SYN-010 21 mg +2 moredrug
Likely dose
SYN-010 21 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared With Placebo on Breath Methane Production in Breath Methane-Positive Subjects With IBS-C
In Brief
A Phase 2 clinical trial evaluating SYN-010 21 mg, SYN-010 42 mg, and 1 other intervention for Irritable Bowel Syndrome With Constipation (IBS-C). Completed, enrolled 63 participants across 1 site.
Detailed Summary
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJul 2015
Primary CompletionOct 2015
Study CompletionNov 2015
TodayJul 2026
First PostedJul 13, 2015
Enrollment StartJun 1, 2015
Primary CompletionOct 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.0 years ago
Interventions
SYN-010 21 mgdrug
SYN-010 42 mgdrug
Placebodrug